RevBio, Inc.
- Industry
- Medical Devices
- Founded Year
- 2014
- Headquarters
- Lowell, Massachusetts, United States
- Employee Count
- 32
Key People
- Brian Hess - CEO and Founder
- Grayson Allen - CFO/COO & Co-Founder
- George Kay - Co-Founder & Chief Scientific Officer
- Andrey Marchenko - Project Engineer & Co-Founder
- Jonathan Reese Slotkin - Advisor
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises experienced professionals with successful backgrounds in medical technology.
The presence of multiple successful MedTech entrepreneurs in the leadership team provides a strong foundation for strategic decision-making and innovation, significantly increasing the likelihood of successful product development and commercialization.
- Clinical Need
-
Aspect: Very Strong
Summary: TETRANITE addresses a significant unmet need in bone repair and fixation.
TETRANITE's ability to bond bone to bone and bone to metal in a wet field environment addresses longstanding challenges in orthopedic and dental surgeries, offering a novel solution that could improve patient outcomes and reduce recovery times.
- Competition
-
Aspect: First mover
Summary: RevBio is pioneering the bone adhesive market with TETRANITE.
As the first company to develop a synthetic bone adhesive like TETRANITE, RevBio has the opportunity to establish a strong market presence and brand recognition, potentially setting the standard for future products in this category.
- Technical Challenge
-
Aspect: Predictable
Summary: The development of TETRANITE involves manageable technical challenges.
While developing a novel bone adhesive involves complex material science and biocompatibility considerations, RevBio's systematic approach and preclinical successes suggest that these challenges are predictable and can be effectively managed.
- Patent
-
Aspect: Very Strong
Summary: RevBio holds a robust patent portfolio protecting TETRANITE.
With multiple U.S. and international patents covering the composition and methods of use for TETRANITE, RevBio has established significant intellectual property barriers to entry for potential competitors, safeguarding its market position.
- Financing
-
Aspect: Well-funded
Summary: RevBio has secured substantial funding from reputable sources.
With over $9 million in grant funding from institutions like the NIH and NASA, RevBio has the financial resources necessary to advance TETRANITE through clinical development and towards commercialization.
- Regulatory
-
Aspect: Pivotal Trial
Summary: TETRANITE is undergoing pivotal clinical trials.
The initiation of pivotal clinical trials for TETRANITE marks a significant step towards regulatory approval, demonstrating the product's safety and efficacy in human subjects, which is essential for market entry.
Opportunity Rollup
- Odds of Success
- 4.15
- Peak Market Share
- 5.45
- Segment CAGR
- 9.9%
- Market Segment
- Orthopedic Biomaterials
- Market Sub Segment
- Bone Adhesives
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.27 |
| 2 | 0.82 |
| 3 | 1.91 |
| 4 | 3.82 |
| 5 | 5.45 |
Key Takeaway
RevBio's TETRANITE presents a promising innovation in bone repair, supported by a strong team, robust patent portfolio, and favorable market dynamics, positioning the company for significant impact in the orthopedic biomaterials market.